MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
ePoster Gallery
P409: National Utilization of Completion Lymph Node Dissection for Melanoma in Patients with Multiple Positive Sentinel Lymph Nodes
Tyler Robinson MD,MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Indiana University
P410: Obesity Associates with Poorer Recurrence-Free Survival Outcomes in Stage III Melanoma Patients Treated with Adjuvant Immunotherapy
Hailey Seibert
P411: Outcomes of Clinically Detected Stage III Melanoma Through Individualized Neoadjuvant (PRADO) Approach At a Single Institution
Drew Erali MD MPH
Roswell Park Comprehensive Cancer Center
P412: Practice Patterns for Performing Sentinel Lymph Node Biopsy for T1b Melanoma Patients
Jessica Cintolo-Gonzalez MD
Division of Surgical Oncology, University of Vermont Medical Center
P413: Prospective Standardized Surveillance of Early-Stage Cutaneous Melanoma Based on Anatomic Staging and Molecular Profiling
Jason Aubrey MD
Corewell Health West - Michigan State University
P414: Provider credentials influence type of biopsy performed but not deep margin status in melanoma
Amelia Van Doren BA
Albany Medical College
P415: Relationship of Mitochondrial Complex I Activity and Response to Immunotherapy Treatment in Melanoma Patients
Annmarie Butare DO
East Carolina University/Brody School of Medicine
P416: Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma
Mary Martos
P417: Sentinel lymph node biopsy remains valuable in the management of presumed high-risk stage II cutaneous melanoma
Hesham Mohamed
Royal Marsden Hospital
P418: Subungual Melanoma: A Half-Century Experience Demonstrating the Prognostic Value of Nodal Staging
Brian Diskin MD
Saint John's Cancer Institute
P419: Surgical Management of the Synchronous Primary in Clinical Stage III Melanoma: Do Surgical Margins for the Primary Tumor Matter?
Adrienne Shannon MD
Moffitt Cancer Center
P420: Validation of a melanoma recurrence model in patients undergoing sentinel lymph node biopsy in an academic community care setting
Julia Downey
P421: An analysis of peritoneal aspirate – Examining the impacts of a 90-minute heated intraperitoneal chemoperfusion in patients with peritoneal malignancy
Neelia Abadi
University of Vermont Larner College of Medicine
P423: Balancing Patient Safety and Cost Savings: Immediate Extubation as a Standard of Care after CRS-HIPEC
Yusuf Ciftci
Johns Hopkins University School of Medicine
P424: Colorectal Peritoneal Metastases Diagnosed Within One Year After Adjuvant Chemotherapy: Association with Poor Prognosis
Jawad Tome
Tel-Aviv Sourasky Medical Center
P425: Combined Retroperitoneal Resection with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer
Shachar Laks
Edith Wolfson Medical Center
P426: Comparative Analysis of Patient Body Surface Area and Peritoneal Surface Area: Implications for HIPEC Dosing
Saim Ali
The Robert Larner, M.D. College of Medicine at The University of Vermont
P428: Does Systemic Chemotherapy Benefit Patients with High-grade Mucinous Appendiceal Neoplasms Undergoing CRS-HIPEC? A National Database Analysis
Salvador Rodriguez Franco MD
University of Colorado Denver | Anschutz Medical Campus